Observational studyBMJ open2023
Patient-reported burden of myasthenia gravis: baseline results of the international prospective, observational, longitudinal real-world digital study MyRealWorld-MG.
Observational study in BMJ open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04176211 (The Impact of Myasthenia Gravis in the Real World), which is not on this map. Cited by 33 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Impact of Myasthenia Gravis in the Real World
Who cites it
33 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Patient-reported health utility in adults with myasthenia gravis: a systematic review and meta-analysis of EQ-5D outcomes.BMC neurology · 2026Pooled it
- Immunoglobulin for myasthenia gravis.The Cochrane database of systematic reviews · 2025Pooled it
- Systematic review of the patient burden of generalised myasthenia gravis in Europe, the Middle East, and Africa.BMC neurology · 2024Pooled it
- Association Between Myasthenia Gravis-Activities of Daily Living (MG-ADL) and EQ-5D-5L Utility Values: The Additional Effect of Efgartigimod on Utilities.Advances in therapy · 2023Trial
- Rozanolixizumab: A Review in AChR or MuSK Autoantibody-Positive Generalised Myasthenia Gravis.CNS drugs · 2026Review
- Telemedical communication patterns in myasthenia gravis in a remote monitoring study.Neurological research and practice · 2026Article
- Myasthenia Gravis (MG) Resource Utilization, Epidemiology, Survival, and Treatment Patterns (MG-REST): Estimating the Clinical and Economic Burden in Ontario, Canada.European journal of neurology · 2026Article
- Interferon regulatory factor 1 enhances T cell differentiation in patients with myasthenia gravis.Neural regeneration research · 2026Article
- Patient Perceptions of Needs and Expectations Regarding the Current Management of Myasthenia Gravis: A Biopsychosocial Study.Neurology and therapy · 2026Article
- Patient- and Caregiver-Reported Burden and Quality of Life in Generalised Myasthenia Gravis: A Multinational Real-World Survey in the Asia-Pacific Region.Neurology and therapy · 2026Article
- Burden of Disease in Myasthenia Gravis: A Targeted Literature Review.Journal of neurology · 2026Review
- Estimating the minimal clinically important difference for the Myasthenia Gravis Quality of Life revised scale (MG-QOL15R).Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026Article
- Pharmacological and speech-language pathology management of dysphagia in patients with myasthenia gravis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Minimal Symptom Expression in Generalized Myasthenia Gravis: A Valuable Patient-Centric Treatment Goal.European journal of neurology · 2026Review
- Healthcare Professionals' Perspectives on Barriers and Facilitators in Care and Rehabilitation of Adults with Myasthenia Gravis in Neurological Departments in Denmark.Journal of multidisciplinary healthcare · 2026Article
- Digital assessment in myasthenia gravis: evidence, validation, and a proposed framework for autoimmune heterogeneity, remote monitoring, and clinical endpoints.Frontiers in immunology · 2026Review
- Efgartigimod for Generalized Myasthenia Gravis and Beyond: A Narrative Review of Its Pharmacological Profile, Clinical Utility, and Expanding Applications.Biomedicines · 2025Review
- Mental Health Experiences and Challenges Among Individuals with Myasthenia Gravis: Insights from Patient-Centered, Qualitative Analyses.Advances in therapy · 2025Review
- Impact of disease activity on quality of life and EQ-5D-3L score in myasthenia gravis: results from the Swedish MG registry.Journal of neurology · 2025Article
- Assessment of functioning using the WHODAS 2.0 among people with myasthenia gravis-associated disability: a nationwide follow-up study.BMC public health · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesMyasthenia gravis (MG) is a rare, chronic, autoimmune neuromuscular disease which can affect functional and mental aspects of health and health-related quality of life (HRQoL). This study aims to obtain detailed knowledge of the impact of MG on HRQoL in a broad population from the perspective of the patient.
designProspective, observational, digital, longitudinal real-world study.
settingAdult patients with MG from seven countries (USA, Japan, Germany, UK, Italy, Spain and Canada) downloaded a mobile application onto their phones and entered data about themselves and their MG. OUTCOME MEASURES: Data was collected using the following general and disease-specific patient-reported outcome measurements: EuroQol 5 Domains Health-Related Quality of Life Questionnaire (EQ-5D-5L), Myasthenia Gravis Activities of Daily Living (MG-ADL), Myasthenia Gravis Quality of Life 15-item revised scale (MG-QoL-15r), Hospital Anxiety and Depression Scale (HADS) and Health Utilities Index III (HUI3). Patients were categorised by their self-assessed Myasthenia Gravis Foundation of America (MGFA) class (I-V).
resultsBaseline results of 841 participants (mean age 47 years, 70% women) are reported . The distribution across the MGFA classes was: 13.9%, 31.0%, 38.1%, 15.5% and 1.6% for classes I-V. The MGFA class was a strong predictor of all aspects of HRQoL, measured with disease-specific and with generic instruments. The domains in which patients with MG most frequently mentioned problems were usual activities, anxiety and depression, tiredness, breathing and vision. The mean total MG-ADL Score was positively associated with increasing MGFA classes: 2.7, 4.4, 6.3 and 8.4 for MGFA classes I-IV. Mean baseline EQ-5D-5L utility was also associated with MGFA classes and was 0.817, 0.766, 0.648 and 0.530 for MGFA class I-IV.
conclusionsMG has a large impact on key aspects of health and HRQoL. The impact of this disease increases substantially with increasing disease severity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.